How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/urinary-tract-infection-caused-by-klebsiella.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Urinary tract infection caused by Klebsiella — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Urinary tract infection caused by Klebsiella (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Urinary tract infection caused by Klebsiella, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Recarbrio	RELEBACTAM	Merck & Co.	Renal Dehydropeptidase Inhibitor [EPC]		2019-01-01
Fetroja	CEFIDEROCOL	Shionogi	Cephalosporin Antibacterial		2019-01-01
Vabomere	VABORBACTAM	Rempex Pharms Inc	beta Lactamase Inhibitor [EPC]		2017-01-01
Zymar	GATIFLOXACIN	Allergan		DNA gyrase, DNA gyrase, DNA gyrase subunit A	2003-01-01
Invanz	ERTAPENEM	Merck & Co.	Penem Antibacterial		2001-01-01
Maxipime	CEFEPIME	Baxter	Cephalosporin Antibacterial		1996-01-01
Maxipime	Cefepime Hydrochloride	Baxter	Cephalosporin	Bacterial cell wall peptidoglycan	1996-01-01
Cystadane	BETAINE	Recordati	Methylating Agent [EPC]		1996-01-01
Cipro	ciprofloxacin	Bayer AG	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Fortaz	Ceftazidime	Pai Holdings Pharm	Third-generation cephalosporin	Bacterial cell wall	1985-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 4 drugs in Urinary tract infection caused by Klebsiella
Pai Holdings Pharm · 2 drugs in Urinary tract infection caused by Klebsiella
Baxter · 2 drugs in Urinary tract infection caused by Klebsiella
Merck & Co. · 2 drugs in Urinary tract infection caused by Klebsiella
Bayer AG · 1 drug in Urinary tract infection caused by Klebsiella
Bristol-Myers Squibb · 1 drug in Urinary tract infection caused by Klebsiella
Mayo Clinic · 1 drug in Urinary tract infection caused by Klebsiella
University Hospital, Lille · 1 drug in Urinary tract infection caused by Klebsiella
Novartis · 1 drug in Urinary tract infection caused by Klebsiella
Allergan · 1 drug in Urinary tract infection caused by Klebsiella
Pfizer · 1 drug in Urinary tract infection caused by Klebsiella
Poitiers University Hospital · 1 drug in Urinary tract infection caused by Klebsiella

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Urinary tract infection caused by Klebsiella:

Cite this brief

Drug Landscape (2026). Urinary tract infection caused by Klebsiella — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/urinary-tract-infection-caused-by-klebsiella. Accessed 2026-06-10.

Urinary tract infection caused by Klebsiella full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing